People: Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

90.04EUR
5 May 2015
Change (% chg)

€-2.25 (-2.44%)
Prev Close
€92.29
Open
€92.43
Day's High
€93.46
Day's Low
€89.80
Volume
3,454,578
Avg. Vol
3,126,009
52-wk High
€99.23
52-wk Low
€69.58

Search Stocks

Meeker, David 

Dr. David P. Meeker, M.D. has been Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team of Sanofi SA since September 1, 2013. He has been Chief Executive Officer of Genzyme since 2010 and served as Chief Executive Officer of Genzyme and Member of the Global Leadership Team of the Company from November 1, 2011 to September 1, 2013. He joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. In 1998, he was appointed Senior Vice President, Medical Affairs, before taking up the role of Senior Vice President for Therapeutics Europe. In 2003, he was appointed President of LSD Therapeutics, where he oversaw the global launches of Aldurazyme, Fabrazyme and Myozyme. He was promoted to Executive Vice President of therapeutics, biosurgery and corporate operations in 2008. Prior to joining Genzyme, he was Director of the pulmonary critical care fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He received his M.D. (a Doctorate of Medicine) degree from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School in 2000.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Search Stocks